Elotuzumab added to pomalidomide prolongs PFS in RRMM
Pomalidomide plus low dose dexamethasone (Pd) is indicated for MM patients who are refractory to or relapse after lenalidomide and bortezomib. Several studies have indicated that adding a third agent to Pd can prolong PFS in these patients. During the Late Breaking oral session Professor Meletios Dimopoulos (National and Kapodistrian University of Athens, Greece) presented results from the phase II ELOQUENT-3 study, the first to compare Pd plus elotuzumab (EPd) to Pd.
Elotuzumab is a monoclonal IgG antibody specific for SLAMF7, which is highly expressed on myeloma cells, and mediates killing of these cells via NK-cells and macrophages. The immunomodulatory drug pomalidomide may synergize with elotuzumab.
Adding elotuzumab to Pd more than doubled the median PFS (10.3 vs 4.7 months, HR 0.54, p=0.0078), and doubled the ORR as well (53% vs 26%). Preliminary OS results show a favorable trend with EPd vs Pd. EPd had a favorable safety profile, with less neutropenia than Pd. Dimopoulos: “This study shows that EPd is a new treatment option for patients with RRMM who have failed treatment with lenalidomide and a proteasome inhibitor.”